Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/11/2022 | $5.00 → $4.00 | Buy | HC Wainwright & Co. |
| 8/25/2021 | $5.00 | Buy | HC Wainwright & Co. |
HOUSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) ("Salarius" or the "Company") today announced that its 2025 Annual Meeting of Stockholders (the "Annual Meeting") scheduled for and convened on December 19, 2025 has been adjourned for the purpose of soliciting additional votes with respect to the proposals described in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission (the "SEC") on November 7, 2025. The required quorum for the transaction of business at the Annual Meeting is 34% of the outstanding shares entitled to vote. There was less than the required voting power represented in perso
The combined Company will move forward as Decoy Therapeutics, Inc. and trade on the NASDAQ Stock Market under the ticker "DCOY" effective in early January 2026 Company to focus on advancing lead antiviral programs, expanding platform validation and achieving multiple data milestones Strategic 2026 roadmap designed to accelerate development, expand pipeline breadth, and drive long-term shareholder value HOUSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) today announced that in connection with its recent combination with Decoy Therapeutics Inc. (Decoy), the Company intends to change its corporate name to Decoy Therapeutics Inc. and its NASDAQ ticker sy
Salarius subsidiary Decoy Therapeutics' influenza fusion inhibitors, designed using its proprietary IMP3ACT™ platform, show excellent in silico free energy binding to the viral target entry protein, supporting potential for anti-flu activity IMP3ACT's demonstrated capability to create a single antiviral therapeutic against influenza, COVID and RSV has potential to position Salarius to address large existing global commercial opportunity CAMBRIDGE, Mass. and HOUSTON, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (Decoy), a preclinical biopharmaceutical subsidiary of Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) that is engineering the next generation of peptide conjugate thera
DEFA14A - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)
8-K - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)
8-K - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)
4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)
4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)
HC Wainwright & Co. reiterated coverage of Salarius Pharmaceuticals with a rating of Buy and set a new price target of $4.00 from $5.00 previously
HC Wainwright & Co. initiated coverage of Salarius Pharmaceuticals with a rating of Buy and set a new price target of $5.00
4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)
4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)
4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)
CAMBRIDGE, Mass. and HOUSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide conjugate therapeutics, announces that Massachusetts Institute of Technology (MIT) Professor and Moderna co-founder Robert S. Langer, ScD will join the company's Scientific Advisory Board (SAB) upon the successful completion of Decoy's merger with Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX). As announced on January 13, 2025, Decoy and Salarius Pharmaceuticals signed a definitive agreement under which Decoy Therapeutics will merge with a wholly owned subsidiary of Salarius Pharmaceuticals, with t
HOUSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other cancers, today announced that Daniela Santiesteban, Ph.D., has been named Director of the Company's new targeted protein degradation program. In this newly created position, Dr. Santiesteban will assume responsibility for overseeing the development of SP-3164, the program's lead drug candidate, and advancing it into clinical trials. Her appointment immediately follows Salarius' recent strategic expansion into the targeted protein degradation field through its acquisitio
HOUSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, will hold a conference call with slides to discuss recent clinical and preclinical data from its lead programs on December 14, 2022 at 11:00 a.m. Eastern time. Management will review recently announced interim results from its ongoing Phase 1/2 trial with seclidemstat in Ewing sarcoma and FET-rearranged sarcomas, as well as new clinical data from MD Anderson Cancer Center's study with seclidemstat plus azacytidine in hematological cancer
60% Confirmed Disease Control Rate1 and 7.4 Months Median Time to Tumor Progression for Ewing Sarcoma First-Relapse Patients No Disease Progression Observed in Either First- or Second-Relapse Ewing Sarcoma Patients Who Achieved Confirmed Disease Control HOUSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using targeted protein inhibition and targeted protein degradation to develop therapies for patients with cancer in need of new treatment options, announces interim clinical trial results from the company's Phase 1/2 trial of its novel oral, reversible, targeted LSD1 inhibitor, seclidemstat, as a treatment fo
HOUSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today reported financial results for the three and six months ended June 30, 2022, and provided a business update. Highlights of the quarter and recent weeks included: Financial Highlights Cash and equivalents were $22.6 million as of June 30, 2022, compared with $29.2 million as of December 31, 2021Tightly managed expenses while progressing toward multiple near-term milestonesNet loss of $4.7 million, or $0.09 per share, compared with net loss of $3.1 million, or $0.07 per share,
SC 13G/A - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)
SC 13G - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)
SC 13G/A - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)